Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
Yves Rinaldi, Anne Laure Pointet, Faiza Khemissa Akouz, Karine Le Malicot, Bidaut Wahiba, Samy Louafi, Alain Gratet, Laurent Miglianico, Hortense Laharie, Karine Bouhier Leporrier, Anne Thirot Bidault, Patrick Texereau, Romain Coriat, Eric Terrebonne, Marie Claude Gouttebel, David Malka, Jean Baptiste Bachet, Côme Lepage, Julien Taieb, Cécile JulienNicolas Barriere, Julie Gigout, Simon Pernot, Céline Lepere, Aziz Zaanan, Géraldine Perkins, Raymond Despax, Jérôme Chamois, Xavier Artignan, Pauline Regnault, Benoît Dupont, Maxime Lesouef, Leila Bengrine Lefevre, Julie Vincent, François Ghiringhelli, Mme E. Barbier, Morgan Andre, Johann Dreanic, Catherine Brezault-Bonnet, Valérie Boige, Antoine Holllebecque, Bruno Valenza, Gildas Phelip, Philippe Dominici, Marion Chauvenet, Frederick Moryoussef, Pierre Luc Etienne, Dominique Besson, Mathilde Martinez, Pamela Biondiani, Benoît Avisse, Marie Pierre Galais, Aurélie Parzy, Salvatore Caruso, Jean François Codoul, Iulia Pripon, Mustapha Atlassi, Oana Cojocarasu, Etienne Suc, Ahmed Bedjaoui, Philippe Houyau, Yann Berge, Dany Gargot, Vincent Bourgeois, Pierre Emmanuel Henneresse, Sandrine Lavau denes, Valérie Lebrun Lyat, Dominique Genet, Jean Martin, Pr Pierre Michel, David Sefrioui, Anne Escande, Louis Marie Dourthe
Research output: Contribution to journal › Article › peer-review
11Scopus
citations
Fingerprint
Dive into the research topics of 'Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)'. Together they form a unique fingerprint.